Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized Study.

Lumry WR, Martinez-Saguer I, Yang WH, Bernstein JA, Jacobs J, Moldovan D, Riedl MA, Johnston DT, Li HH, Tang Y, Schranz J, Lu P, Vardi M, Farkas H; SAHARA study group.

J Allergy Clin Immunol Pract. 2019 May - Jun;7(5):1610-1618.e4. doi: 10.1016/j.jaip.2019.01.021. Epub 2019 Jan 23.

2.

Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings.

Craig T, Lumry W, Cicardi M, Zuraw B, Bernstein JA, Anderson J, Jacobs J, Riedl MA, Manning ME, Banerji A, Gower RG, Caballero T, Farkas H, Feuersenger H, Jacobs I, Machnig T, Longhurst H; COMPACT Investigators.

J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6):2035-2038. doi: 10.1016/j.jaip.2019.01.007. Epub 2019 Jan 17. No abstract available.

3.

Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies.

Busse PJ, Farkas H, Banerji A, Lumry WR, Longhurst HJ, Sexton DJ, Riedl MA.

BioDrugs. 2019 Feb;33(1):33-43. doi: 10.1007/s40259-018-0325-y. Review.

4.

Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.

Banerji A, Riedl MA, Bernstein JA, Cicardi M, Longhurst HJ, Zuraw BL, Busse PJ, Anderson J, Magerl M, Martinez-Saguer I, Davis-Lorton M, Zanichelli A, Li HH, Craig T, Jacobs J, Johnston DT, Shapiro R, Yang WH, Lumry WR, Manning ME, Schwartz LB, Shennak M, Soteres D, Zaragoza-Urdaz RH, Gierer S, Smith AM, Tachdjian R, Wedner HJ, Hebert J, Rehman SM, Staubach P, Schranz J, Baptista J, Nothaft W, Maurer M; HELP Investigators.

JAMA. 2018 Nov 27;320(20):2108-2121. doi: 10.1001/jama.2018.16773. Erratum in: JAMA. 2019 Apr 23;321(16):1636.

5.

Treatment patterns and healthcare resource utilization among patients with hereditary angioedema in the United States.

Riedl MA, Banerji A, Manning ME, Burrell E, Joshi N, Patel D, Machnig T, Tai MH, Watson DJ.

Orphanet J Rare Dis. 2018 Oct 12;13(1):180. doi: 10.1186/s13023-018-0922-3.

6.

Long-term prophylaxis therapy in patients with hereditary angioedema with C1 inhibitor deficiency.

Craig T, Busse P, Gower RG, Johnston DT, Kashkin JM, Li HH, Lumry WR, Riedl MA, Soteres D.

Ann Allergy Asthma Immunol. 2018 Dec;121(6):673-679. doi: 10.1016/j.anai.2018.07.025. Epub 2018 Jul 27. Review.

PMID:
30056152
7.

Population pharmacokinetics of subcutaneous C1-inhibitor for prevention of attacks in patients with hereditary angioedema.

Pawaskar D, Tortorici MA, Zuraw B, Craig T, Cicardi M, Longhurst H, Li HH, Lumry WR, Martinez-Saguer I, Jacobs J, Bernstein JA, Riedl MA, Katelaris CH, Keith PK, Feussner A, Sidhu J.

Clin Exp Allergy. 2018 Oct;48(10):1325-1332. doi: 10.1111/cea.13220. Epub 2018 Aug 26.

PMID:
29998524
8.

Threshold-stimulated kallikrein activity distinguishes bradykinin- from histamine-mediated angioedema.

Lara-Marquez ML, Christiansen SC, Riedl MA, Herschbach J, Zuraw BL.

Clin Exp Allergy. 2018 Nov;48(11):1429-1438. doi: 10.1111/cea.13219. Epub 2018 Aug 21.

PMID:
29957871
9.

Efficacy of recombinant human C1 esterase inhibitor across anatomic locations in acute hereditary angioedema attacks.

Baker JW, Bernstein JA, Harper JR, Relan A, Riedl MA.

Allergy Asthma Proc. 2018 Sep 28;39(5):359-364. doi: 10.2500/aap.2018.39.4151. Epub 2018 Jun 28.

PMID:
29954477
10.

Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study.

Riedl MA, Aygören-Pürsün E, Baker J, Farkas H, Anderson J, Bernstein JA, Bouillet L, Busse P, Manning M, Magerl M, Gompels M, Huissoon AP, Longhurst H, Lumry W, Ritchie B, Shapiro R, Soteres D, Banerji A, Cancian M, Johnston DT, Craig TJ, Launay D, Li HH, Liebhaber M, Nickel T, Offenberger J, Rae W, Schrijvers R, Triggiani M, Wedner HJ, Dobo S, Cornpropst M, Clemons D, Fang L, Collis P, Sheridan WP, Maurer M.

Allergy. 2018 Sep;73(9):1871-1880. doi: 10.1111/all.13466. Epub 2018 Jun 17.

11.

Hereditary angioedema from the patient's perspective: A follow-up patient survey.

Banerji A, Li Y, Busse P, Riedl MA, Holtzman NS, Li HH, Davis-Lorton M, Bernstein JA, Frank M, Castaldo AJ, Long J, Zuraw B, Lumry W, Christiansen S.

Allergy Asthma Proc. 2018 May 1;39(3):212-223. doi: 10.2500/aap.2018.39.4123.

12.

C1 esterase inhibitor concentrates and attenuated androgens - Authors' reply.

Riedl MA, Relan A, Harper JR, Cicardi M.

Lancet. 2018 Apr 7;391(10128):1356. doi: 10.1016/S0140-6736(18)30573-7. No abstract available.

PMID:
29636270
13.

Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.

Lumry WR, Craig T, Zuraw B, Longhurst H, Baker J, Li HH, Bernstein JA, Anderson J, Riedl MA, Manning ME, Keith PK, Levy DS, Caballero T, Banerji A, Gower RG, Farkas H, Lawo JP, Pragst I, Machnig T, Watson DJ.

J Allergy Clin Immunol Pract. 2018 Sep - Oct;6(5):1733-1741.e3. doi: 10.1016/j.jaip.2017.12.039. Epub 2018 Jan 31.

14.

An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension.

Riedl MA, Bernstein JA, Craig T, Banerji A, Magerl M, Cicardi M, Longhurst HJ, Shennak MM, Yang WH, Schranz J, Baptista J, Busse PJ.

Clin Transl Allergy. 2017 Oct 6;7:36. doi: 10.1186/s13601-017-0172-9. eCollection 2017.

15.

Vedolizumab in Patients With Common Variable Immune Deficiency and Gut Inflammation.

Boland BS, Riedl MA, Valasek MA, Crowe SE, Sandborn WJ.

Am J Gastroenterol. 2017 Oct;112(10):1621. doi: 10.1038/ajg.2017.246. No abstract available.

16.

Recombinant human C1 esterase inhibitor for acute hereditary angioedema attacks with upper airway involvement.

Riedl MA, Li HH, Cicardi M, Harper JR, Relan A.

Allergy Asthma Proc. 2017 Nov 13;38(6):462-466. doi: 10.2500/aap.2017.38.4090. Epub 2017 Sep 13.

PMID:
28903805
17.

Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial.

Riedl MA, Grivcheva-Panovska V, Moldovan D, Baker J, Yang WH, Giannetti BM, Reshef A, Andrejevic S, Lockey RF, Hakl R, Kivity S, Harper JR, Relan A, Cicardi M.

Lancet. 2017 Sep 30;390(10102):1595-1602. doi: 10.1016/S0140-6736(17)31963-3. Epub 2017 Jul 25.

PMID:
28754491
18.

Utility of minor determinants for skin testing in inpatient penicillin allergy evaluation.

Geng B, Eastman JJ, Mori K, Braskett M, Riedl MA.

Ann Allergy Asthma Immunol. 2017 Sep;119(3):258-261. doi: 10.1016/j.anai.2017.06.009. Epub 2017 Jul 23.

PMID:
28743423
19.

Angioedema: Challenges and Insights.

Riedl MA.

Immunol Allergy Clin North Am. 2017 Aug;37(3):xv-xvi. doi: 10.1016/j.iac.2017.05.001. No abstract available.

PMID:
28687115
20.

Emerging Therapies in Hereditary Angioedema.

Chen M, Riedl MA.

Immunol Allergy Clin North Am. 2017 Aug;37(3):585-595. doi: 10.1016/j.iac.2017.03.003. Review. Erratum in: Immunol Allergy Clin North Am. 2017 Nov;37(4):xiii.

Supplemental Content

Loading ...
Support Center